Eptinezumab Offers Hope for Resistant Chronic Migraines in Australia
- MigraineMind
- Dec 4, 2025
- 1 min read
Research Summary
A new study published in the journal Headache explores the real-world effectiveness of eptinezumab for treatment-resistant chronic migraine prevention in Australia. This retrospective audit involved 54 patients and revealed significant reductions in monthly migraine days (MMD) from 23 to 15 days and monthly headache days (MHD) from 27 to 19 days three months after treatment. Use of acute analgesics also decreased from 16 to 11 days. Impressively, 94% of participants experienced no immediate adverse events. These findings suggest eptinezumab is a safe and effective option for patients unresponsive to other treatments, though larger, longer-term studies are necessary for confirmation.
Study Details
👥 Research Team: Gunasekera L et al.
📚 Published In: Headache
📅 Publication Date: 2025 Dec 2
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.